Trinity biotech launches its continuous glucose monitoring microsite to showcase its innovative & differentiated technology

Dublin, june 03, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“cgm”) microsite - https://cgm.trinitybiotech.com. this website will be used to provide the company's stakeholders with key insights into the company's vision for the development of the next generation of its recently acquired cgm biosensor technology and artificial intelligence (“ai”) driven health & wellness analytics platform, as well as providing additional visibility on the international commercialisation of these solutions.
TRIB Ratings Summary
TRIB Quant Ranking